imalumab (BAX069) / Takeda - LARVOL DELTA

Integrating In Silico and In Vitro Tools for Optimized Antibody Development-Design of Therapeutic Anti-oxMIF Antibodies. (PubMed, Antibodies (Basel)) - "Altogether, this study shows that a small number of well-selected mutations was sufficient to substantially improve the biophysicochemical properties of imalumab."

Journal • Preclinical • MIF

Preclinical Evaluation of ON203, A Novel Bioengineered mAb Targeting Oxidized Macrophage Migration Inhibitory Factor as an Anticancer Therapeutic. (PubMed, Mol Cancer Ther) - "In vivo, ON203 mAb demonstrated superior efficacy over imalumab in both prophylactic and established prostate cancer (PC3) mouse xenograft models. In summary, our data highlight the potential of the second-generation anti-oxMIF mAb ON203 as a promising immunotherapy for patients with solid tumors, warranting clinical evaluation."

IO biomarker • Journal • Preclinical • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • MIF

ON203: A new antibody targeting the oxidized form of macrophage migration inhibitory factor demonstrates antitumorigenic activity and TME modulation in patient-derived CRC tumoroids (ESMO-GI 2022) - "Tissue penetration and target occupancy analyses demonstrated specific binding of imalumab to oxMIF in CRC liver metastases. These findings are in line with in vivo efficacy models. Therefore, ON203 has a high potential to become a new treatment option for patients with colorectal cancers as a standalone therapy or in combination with checkpoint inhibitors, chemotherapeutics, anti-angiogenic drugs, or kinase inhibitors."

Clinical • Colorectal Adenocarcinoma • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • CD8 • FCGR2A • FCGR2B • GZMB • IL10 • LAMP1 • MIF • TNFA

Anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody imalumab (BAX69) in advanced solid tumors: Final results of first-in-human phase 1 study (ESMO 2016) - P1; "Conclusions: Imalumab 10 mg/kg IV weekly was well tolerated and showed single-agent antitumor activity in these pts."

Clinical • Biosimilar • Colorectal Cancer • Gastrointestinal Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer

Phase I study of Imalumab (BAX69), a Fully Human Recombinant Anti-oxidized Macrophage Migration Inhibitory Factor Antibody in Advanced Solid Tumors. (PubMed, Br J Clin Pharmacol) - P1; "Imalumab had a maximum tolerated dose of 37.5 mg/kg every 2 weeks in patients with advanced solid tumors, with a biologically active dose of 10 mg/kg weekly. Further investigation will help define the role of oxMIF as a cancer treatment target."

Journal • P1 data